NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$2.71
+0.0300 (+1.12%)
At Close: May 03, 2024
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
07:30am, Monday, 25'th Jan 2021
2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
08:00am, Monday, 04'th Jan 2021
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
09:47am, Tuesday, 15'th Dec 2020
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
07:30am, Thursday, 10'th Dec 2020
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
07:00am, Monday, 16'th Nov 2020
Data released today expands on November 15, 2020 AASLD presentation
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warrante
Arbutus to Present at Jefferies Virtual London Healthcare Conference
08:00am, Tuesday, 10'th Nov 2020
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chr
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
03:11pm, Thursday, 05'th Nov 2020
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
The Arbutus Biopharma (NASDAQ:ABUS) Share Price Is Up 136% And Shareholders Are Boasting About It
12:59pm, Monday, 17'th Aug 2020
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
ROCE Insights For Arbutus Biopharma
03:27pm, Wednesday, 12'th Aug 2020
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 sales of $1.51 million. Earnings fell to a loss of $13.03 million, resulting in a 0.08% decrease from last quarter. In Q1, Arbutus Biopharma brought in $1.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
03:30pm, Monday, 10'th Aug 2020
Is (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
12:55pm, Friday, 07'th Aug 2020
Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Arbutus Biopharma Q2 Earnings
11:50am, Friday, 07'th Aug 2020
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65% over the past year to ($0.25), which miss
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
11:30am, Friday, 07'th Aug 2020
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibito
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Wednesday, 05'th Aug 2020
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron
